GW4869 Can Inhibit Epithelial-Mesenchymal Transition and Extracellular HSP90α in Gefitinib-Sensitive NSCLC Cells

References

• Hyuna S, Jacques F, Me RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Ke E, Zhou Q, Wu Y. Emerging Paradigms in Targeted Treatments for Asian Patients with NSCLC. Expert Opin Pharmacother. 2015;16(8):1167–1176. doi:10.1517/14656566.2015.1040391
   PubMed Web of Science ®Google Scholar
• Rawluk J, Waller CF. Gefitinib. Recent Results Cancer Res. 2018;211:235–246.
   PubMedGoogle Scholar
• Johnson M, Garassino MC, Mok T, et al. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel therapies. Lung Cancer. 2022;170:41–51. doi:10.1016/j.lungcan.2022.05.011
   PubMed Web of Science ®Google Scholar
• Wu SG, Shih JY. Management of Acquired Resistance to EGFR TKI-targeted Therapy in Advanced Non-Small Cell Lung Cancer. Mol Cancer. 2018;17:38. doi:10.1186/s12943-018-0777-1
   PubMed Web of Science ®Google Scholar
• Esposito AR, Pasquale R, Sacco A, et al. Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib. Cancers. 2019;11(10):1431. doi:10.3390/cancers11101431
   PubMed Web of Science ®Google Scholar
• Li W, Tsen F, Sahu D, et al. Extracellular Hsp90 (eHsp90) as the Actual Target in Clinical Trials: intentionally Or Unintentionally. Int Rev Cell Mol Biol. 2013;303:203–235.
   PubMed Web of Science ®Google Scholar
• Eguchi T, Taha EA, Calderwood SK, et al. Novel Model of Cancer Drug Resistance: oncosomal Release of Cytotoxic and Antibody-Based Drugs. Biology. 2020;9(3):47. doi:10.3390/biology9030047
   PubMedGoogle Scholar
• Catalano M, O’Driscoll L. Inhibiting Extracellular Vesicles Formation and Release: a Review of EV Inhibitors. J Extracell Vesicles. 2020;9:1703244.
   PubMed Web of Science ®Google Scholar
• Eguchi T, Sogawa C, Ono K, et al. Cell Stress Induced Stressome Release Including Damaged Membrane Vesicles and Extracellular HSP90 by Prostate Cancer Cells. Cells. 2020;10(1):9. doi:10.3390/cells10010009
   PubMedGoogle Scholar
• Jakobsen KR, Demuth C, Sorensen BS, et al. The Role of Epithelial to Mesenchymal Transition in Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Transl Lung Cancer Res. 2016;5(2):172–182. doi:10.21037/tlcr.2016.04.07
   PubMed Web of Science ®Google Scholar
• Nowak E, Bednarek I. Aspects of the Epigenetic Regulation of EMT Related to Cancer Metastasis. Cells. 2021;10.3435.
   Google Scholar
• Jolly MK, Celia-Terrassa T. Dynamics of Phenotypic Heterogeneity Associated with EMT and Stemness during Cancer Progression. J Clin Med. 2019;9(1):8. doi:10.3390/jcm9010008
   PubMedGoogle Scholar
• Shibue T, Weinberg RA. EMT, CSCs, and Drug Resistance: the Mechanistic Link and Clinical Implications. Nat Rev Clin Oncol. 2017;14(10):611–629. doi:10.1038/nrclinonc.2017.44
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang T, Qin S, et al. Effects of UPF1 expression on EMT process by targeting E‑cadherin, N‑cadherin, Vimentin and Twist in a hepatocellular carcinoma cell line. Mol Med Rep. 2019;19(3):2137–2143. doi:10.3892/mmr.2019.9838
   PubMed Web of Science ®Google Scholar
• Xu K, Zhang C, Du T, et al. Progress of exosomes in the diagnosis and treatment of lung cancer. Biomed Pharmacother. 2021;134:111111. doi:10.1016/j.biopha.2020.111111
   PubMed Web of Science ®Google Scholar
• Trepel J, Mollapour M, Giaccone G, et al. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10(8):537–549. doi:10.1038/nrc2887
   PubMed Web of Science ®Google Scholar
• Huang B, Pan J, Liu H, et al. High Expression of Plasma Extracellular HSP90α is Associated With the Poor Efficacy of Chemotherapy and Prognosis in Small Cell Lung Cancer. Front Mol Biosci. 2022;9:913043. doi:10.3389/fmolb.2022.913043
   PubMed Web of Science ®Google Scholar
• Lang BJ, Guerrero-Giménez ME, Prince TL, et al. Heat Shock Proteins are Essential Components in Transformation and Tumor Progression: cancer Cell Intrinsic Pathways and Beyond. Int J Mol Sci. 2019;20(18):4507. doi:10.3390/ijms20184507
   PubMed Web of Science ®Google Scholar
• Dong HM, Le YQ, Wang YH, et al. Extracellular Heat Shock Protein 90Alpha Mediates HDM-induced Bronchial Epithelial Barrier Dysfunction by Activating RhoA/MLC Signaling. Respir Res. 2017;18(1):111. doi:10.1186/s12931-017-0593-y
   PubMedGoogle Scholar
• Hoter A, El-Sabban ME, Naim HY. The HSP90 Family: structure, Regulation, Function, and Implications in Health and Disease. Int J Mol Sci. 2018;19(9):2560. doi:10.3390/ijms19092560
   PubMed Web of Science ®Google Scholar
• Taha EA, Ono K, Eguchi T. Roles of Extracellular HSPs as Biomarkers in Immune Surveillance and Immune Evasion. Int J Mol Sci. 2019;20(18):4588. doi:10.3390/ijms20184588
   PubMed Web of Science ®Google Scholar
• Den RB, Lu B. Heat Shock Protein 90 Inhibition: rationale and Clinical Potential. Ther Adv Med Oncol. 2012;4(4):211–218. doi:10.1177/1758834012445574
   PubMed Web of Science ®Google Scholar
• Chen J, Rong N, Liu M, et al. The Exosome-Like Vesicles Derived From Androgen Exposed-Prostate Stromal Cells Promote Epithelial Cells Proliferation and Epithelial-Mesenchymal Transition. Toxicol Appl Pharmacol. 2021;411:115384. doi:10.1016/j.taap.2020.115384
   PubMed Web of Science ®Google Scholar
• Ruizhu S, Zhansheng H. Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma. Oncol Lett. 2022;24(5):408. doi:10.3892/ol.2022.13528
   PubMed Web of Science ®Google Scholar
• Liao BC, Griesing S, Yang JC. Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. Ther Adv Med Oncol. 2019;11:1758835919890286. doi:10.1177/1758835919890286
   Web of Science ®Google Scholar
• Ji W, Choi YJ, Kang M-H. Efficacy of the CDK7 Inhibitor On EMT-Associated Resistance to 3Rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines. Cells. 2020;9(12):2596. doi:10.3390/cells9122596
   PubMed Web of Science ®Google Scholar
• Dai B, Fan M, Yu R, et al. Novel Diphenyl Urea Derivative Serves as an Inhibitor On Human Lung Cancer Cell Migration by Disrupting EMT Via Wnt/beta-catenin and PI3K/Akt Signaling. Toxicol In Vitro. 2020;69:105000. doi:10.1016/j.tiv.2020.105000
   PubMed Web of Science ®Google Scholar
• Lauwers E, Wang YC, Gallardo R, et al. Hsp90 Mediates Membrane Deformation and Exosome Release. Mol Cell. 2018;71(5):689–702. doi:10.1016/j.molcel.2018.07.016
   PubMed Web of Science ®Google Scholar
• Chen R, Qian Z, Xu X, et al. Exosomes-Transmitted miR-7 Reverses Gefitinib Resistance by Targeting YAP in Non-Small-Cell Lung Cancer. Pharmacol Res. 2021;165:105442. doi:10.1016/j.phrs.2021.105442
   PubMed Web of Science ®Google Scholar
• You J, Li M, Cao L, et al. Snail1-Dependent Cancer-Associated Fibroblasts Induce Epithelial-Mesenchymal Transition in Lung Cancer Cells Via Exosomes. QJM. 2019;112(8):581–590. doi:10.1093/qjmed/hcz093
   PubMed Web of Science ®Google Scholar
• Yang Y, Li CW, Chan LC, et al. Exosomal PD-L1 Harbors Active Defense Function to Suppress T Cell Killing of Breast Cancer Cells and Promote Tumor Growth. Cell Res. 2018;28(8):862–864. doi:10.1038/s41422-018-0060-4
   PubMed Web of Science ®Google Scholar
• Tallon C, Hollinger KR. Nipping disease in the bud: nSMase2 inhibitors as therapeutics in extracellular vesicle-mediated diseases. Drug Discov Today. 2021;26(7):1656–1668. doi:10.1016/j.drudis.2021.03.025
   PubMed Web of Science ®Google Scholar
• Ghandour B, Dbaibo G, Darwiche N. The unfolding role of ceramide in coordinating retinoid-based cancer therapy. Biochem J. 2021;478(19):3621–3642. doi:10.1042/BCJ20210368
   PubMed Web of Science ®Google Scholar
• Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with antiPD-1 response. Nature. 2018;560(7718):382. doi:10.1038/s41586-018-0392-8
   PubMed Web of Science ®Google Scholar
• Poggio M, Hu T, Pai CC, et al. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell. 2019;177(2):414–27 e413. doi:10.1016/j.cell.2019.02.016
   PubMed Web of Science ®Google Scholar
• Wang G, Xie L, Li B, et al. A nanounit strategy reverses immune suppression of exosomal PD-L1 and is associated with enhanced ferroptosis. Nat Commun. 2021;12(1):5733. doi:10.1038/s41467-021-25990-w
   PubMed Web of Science ®Google Scholar
• Rojas C, Barnaeva E, Thomas AG, et al. DPTIP, a newly identifed potent brain penetrant neutral sphingomyelin- nase 2 inhibitor, regulates astrocyte-peripheral immune communica- tion following brain inflammation. Sci Rep. 2018;8(1):17715. doi:10.1038/s41598-018-36144-2
   PubMedGoogle Scholar
• Rojas C, Sala M, Thomas AG, et al. A novel and potent brain penetrant inhibitor of extracellular vesicle release. Br J Pharmacol. 2019;176(19):3857–3870. doi:10.1111/bph.14789
   PubMed Web of Science ®Google Scholar
• Wang F, Oudaert I, Tu C, et al. System Xc inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance. Cancer Lett. 2022;535:215649. doi:10.1016/j.canlet.2022.215649
   PubMed Web of Science ®Google Scholar
• Wong DS, Jay DG. Emerging Roles of Extracellular Hsp90 in Cancer. Adv Cancer Res. 2016;129:141–163.
   PubMed Web of Science ®Google Scholar